[1] Bertoletti A,Ferrari C. Adaptive immunity in HBV infection. J Hepatol, 2016,64(1 Suppl): S71-S83.
[2] Thimme R, Wieland S, Steiger C, et al. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol, 2003, 77(1): 68-76.
[3] Fanning GC, Zoulim F, Hou J, et al., Therapeutic strategies for hepatitis B virus infection: towards a cure. Nat Rev Drug Discov, 2019, 18(11): 827-844.
[4] Zhou YZ, Chang YN, He Y, et al. Correlation of qAnti-HBc with antiviral efficacy in children with chronic hepatitis B and exploration of its possible immune mechanism. Zhonghua Gan Zang Bing Za Zhi, 2021. 29(9): 837-843.
[5] Hou FQ, Song LW, Yuan Q, et al. Quantitative hepatitis B core antibody level is a new predictor for treatment response in HBeAg-positive chronic hepatitis B patients receiving peginterferon. Theranostics, 2015. 5(3): 218-226.
[6] Lu FM, Wang J, Chen XM, et al. Application of the new serum markers in the research and development of innovative hepatitis B drugs. Zhonghua Gan Zang Bing Za Zhi, 2020. 28(8):649-653.
[7] Chi H, Li Z, Hansen BE, et al. Serum Level of Antibodies Against Hepatitis B Core Protein Is Associated With Clinical Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy. Clin Gastroenterol Hepatol, 2019,17(1): 182-191.e1.
[8] 杨柳,宋红丽. 乙肝病毒感染慢性化与相关免疫细胞. 实用医学杂志, 2016. 32(06): 1022-1024.
[9] Lunemann S, Malone DF, Hengst J, et al. Compromised function of natural killer cells in acute and chronic viral hepatitis. J Infect Dis, 2014,209(9): 1362-1373.
[10] Sun C,Sun H, Zhang C,et al. NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma. Cell Mol Immunol, 2015,12(3): 292-302.
[11] Li F, Wei H, Wei H, et al, Blocking the natural killer cell inhibitory receptor NKG2A increases activity of human natural killer cells and clears hepatitis B virus infection in mice. Gastroenterology, 2013,144(2): 392-401.
[12] Ma SW, Huang X, Li YY, et al. High serum IL-21 levels after 12 weeks of antiviral therapy predict HBeAg seroconversion in chronic hepatitis B. J Hepatol, 2012. 56(4):775-781.
[13] Li Y, Tang L, Guo L, et al., CXCL13-mediated recruitment of intrahepatic CXCR5(+)CD8(+) T cells favors viral control in chronic HBV infection. J Hepatol, 2020. 72(3): 420-430.
[14] 高子翔,沈中良,刘晶,等. 细胞因子在慢性乙型肝炎治疗中的研究进展. 临床肝胆病杂志, 2022,38(08): 1710-1715.
[15] Tang L, Chen C, Gao X, et al. Interleukin 21 Reinvigorates the Antiviral Activity of Hepatitis B Virus (HBV)-Specific CD8+ T Cells in Chronic HBV Infection. J Infect Dis, 2019,219(5): 750-759.
[16] Yang L, Jia S, Shao X, et al. Interleukin-35 modulates the balance between viral specific CD4(+)CD25(+)CD127(dim/-) regulatory T cells and T helper 17 cells in chronic hepatitis B virus infection. Virol J, 2019,16(1): 48.
[17] Xia M, Liao G, Chen H, et al. Plasma CXCL13 is a predictive factor for HBsAg loss and clinical relapse after discontinuation of nucleos(t)ide analogue treatment. Clin Immunol, 2019,198:31-38.
[18] Maini MK, Boni C, Lee CK, et al. The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med, 2000,191(8):1269-1280.
[19] Schuch A, Salimi Alizei E, Heim K, et al. Phenotypic and functional differences of HBV core-specific versus HBV polymerase-specific CD8+ T cells in chronically HBV-infected patients with low viral load. Gut, 2019,68(5): 905-915.
[20] Aliabadi E, Urbanek-Quaing M, Maasoumy B, et al. Impact of HBsAg and HBcrAg levels on phenotype and function of HBV-specific T cells in patients with chronic hepatitis B virus infection. Gut, 2022,71(11): 2300-2312.
[21] Le Bert N, Gill US, Hong M, et al. Effects of Hepatitis B Surface Antigen on Virus-Specific and Global T Cells in Patients With Chronic Hepatitis B Virus infection. Gastroenterology, 2020. 159(2): 652-664.
[22] Salimzadeh L, Le Bert N, Dutertre CA, et al. PD-1 blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infection. J Clin Invest, 2018,128(10):4573-4587.
[23] Bénéchet AP, De Simone G, Di Lucia P, et al. Dynamics and genomic landscape of CD8(+) T cells undergoing hepatic priming. Nature, 2019, 574(7777): 200-205.
[24] Isogawa M, Chung J, Murata Y, et al. CD40 activation rescues antiviral CD8+ T cells from PD-1-mediated exhaustion. PLoS Pathog, 2013,9(7): e1003490.
[25] Brümmer LE, Katzenschlager S, Gaeddert M, et al., Accuracy of novel antigen rapid diagnostics for SARS-CoV-2: A living systematic review and meta-analysis. PLoS Med, 2021,18(8): e1003735.
[26] Tan AT, Lim JM, Bert NL, et al. Rapid measurement of SARS-CoV-2 spike T cells in whole blood from vaccinated and naturally infected individuals. J Clin Invest, 2021,131(17):e152379. |
